NEW YORK (GenomeWeb News) – Precision BioSciences today said it has filed a fourth lawsuit against Cellectis and a number of its affiliates alleging patent infringement.
The company filed its lawsuit in US District Court for the Eastern District of North Carolina claiming Cellectis infringes on US Patent No. 8,124,369, which relates to Precision Bio's Directed Nuclease Editor genome engineering technology.
The Research Triangle Park, N.C.-based genetic engineering company is asking for monetary damages, a permanent injunction against Cellectis from making, using, selling, offering for sale, or importing infringing engineered meganucleases in the US.
Precision Bio filed two lawsuits against the French firm last week as well as one in the fall.